Deals this week: Riptide Bioscience, Turning Pharmaceuticals, Aralez Pharmaceuticals

Riptide Bioscience and National Cancer Institute (NCI) have entered a three-year co-operative research and development agreement.

The agreement enables the two partners to further advance the Riptide Bioscience’s Peptide rp-182 through the pre-clinical studies and develop it as a treatment for pancreatic cancer.

Turning Pharmaceuticals and Washington University have entered a sponsored research agreement to develop new treatments for toxoplasmosis.

The agreement allows Turning Pharma to develop novel treatments for a life-threatening infection.

Aralez Pharmaceuticals plans to strengthen its presence in cardiovascular disease treatments by acquiring US rights to Toprol-Xl and its authorised generic form from AstraZeneca.

According to the agreement, Aralez Pharma will finance the transaction and will be responsible for an upfront payment of $175 million to AstraZeneca to acquire the rights to Toprol-XL tablets, and will also pay an additional $48 million in milestone, sales-related payments and royalties.

Concordia International plans to raise gross proceeds of $266.05 million through the issue of five and a half-year senior first lien notes.

The company intends to use the proceeds to further advance its product development pipeline.

Samsung Biologics has announced the initial public offering of its common stock shares.

The company expects to raise gross proceeds of up to $2 billion from the offering and utilise the funds to expand its position in biopharmaceutical market, to double its bioreactor capacity and also repay its debts.

---

Image: Aralez Pharmaceuticals Inc plans to acquire US rights to Toprol-Xl from AstraZeneca. Photo: Courtesy of Erik031.